85
Participants
Start Date
November 13, 2019
Primary Completion Date
December 10, 2024
Study Completion Date
December 10, 2024
PF-06940434
PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
PF-06801591
PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
National Taiwan University Hospital, Taipei
Southern Medical Day Care Centre, Wollongong
Taipei Veterans General Hospital, Taipei
Greenebaum Comprehensive Cancer Center, Baltimore
Duke Univ. Medical Center/Duke Cancer Center, Durham
Investigational Chemotherapy Service, Durham
Siteman Cancer Center - North County, Florissant
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine Siteman Cancer Center, St Louis
Siteman Cancer Center - South County, St Louis
Siteman Cancer Center - West County, Creve Coeur
Siteman Cancer Center - St. Peters, City of Saint Peters
National Cheng Kung University Hospital, Tainan City
The University of Texas MD Anderson Cancer Center, Houston
NEXT Oncology, San Antonio
Univerzitna nemocnica Bratislava, Bratislava
HonorHealth Research Institute, Scottsdale
HonorHealth Scottsdale Shea Medical Center, Scottsdale
Ronald Reagan UCLA Medical Center, Los Angeles
UCLA Hematology Oncology, Los Angeles
UCLA Hematology/Oncology, Santa Monica
Fred Hutchinson Cancer Center, Seattle
University of Washington Medical Center, Seattle
Onkologicky ustav sv. Alzbety, s.r.o., Bratislava
Narodny ustav srdcovych a cievnych chorob, a.s., Bratislava
MR Poprad s.r.o., Komárno
KARDIO, s.r.o., Poprad
POKO Poprad, s.r.o., Ambulancia klinickej onkologie, Poprad
Nemocnica Poprad a.s., Poprad
Asan Medical Center, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Lead Sponsor
Pfizer
INDUSTRY